US Patent Application 20100003279 - VACCINE FOR IN OVO INOCULATION
InventorsAssigneeUS Classes424/207.1, Retroviridae (e.g., feline leukemia virus, bovine leukemia virus, avian leukosis virus, equine infectious anemia virus, Rous sarcoma virus, HTLV-I, etc.)424/204.1, Virus or component thereof424/232.1, Poxviridae (e.g., smallpox virus, avian pox virus, fowlpox virus, rabbit myxoma virus, vaccinia virus, etc.)424/229.1, Herpetoviridae (e.g., herpesvirus, Marek`s disease virus, laryngotracheitis virus, infectious bovine rhinotracheitis virus (IBR), infectious pustular vulvovaginitis virus, bovine herpes virus type 1, Aujeszky`s disease virus, feline rhinotracheitis virus, feline herpes virus, etc.)424/216.1, Calciviridae or picornaviridae, except hepatitis A virus (e.g., foot-and- mouth disease virus (FMDV), coxsackievirus, echovirus, avian encephalomyelitis virus, Mengovirus, etc.)424/233.1, Adenoviridae, adeno-like virus, or Parvoviridae (e.g., adenovirus, canine parvovirus, mink enteritis virus, hemorrhagic enteritis virus, feline panleukopenia virus, egg drop syndrome virus, etc.)424/214.1, Newcastle disease virus424/222.1, Infectious bronchitis virus (IBV)424/209.1, Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.)424/215.1Reoviridae (e.g., rotavirus, reovirus, orbivirus, avian proventriculitis virus, bluetongue virus, Colorado tick fever virus, etc.)Attorney, Agent or FirmForeign Documents
International ClassesA61K 39/21A61K 39/12 A61K 39/275 A61K 39/255 A61K 39/125 A61K 39/235 A61P 31/12 A61K 39/17 A61K 39/215 A61K 39/145 A61K 39/15 Abstract textA purpose of the present invention is to provide a vaccine for in ovo inoculation effective for prevention of any fowl viral diseases. A fowl vaccine for in ovo inoculation with high efficacy in view of safety as well wherein, by holding such live viruses on a virus-adsorbing agent through adsorption that have been difficult for practical usage as a vaccine for in ovo inoculation, viral growth in embryonated chicken eggs after in ovo inoculation is retarded to thereby reduce pathogenicity of the viruses to embryo to avoid reduction in hatching rate and to alleviate severity in clinical symptoms after hatching. A virus-adsorbing agent to be used in the vaccine includes an aluminum compound such as aluminum hydroxide gel, potassium alum and the like. |
| ||||||||||||||
